Ethical complexities in standard of care randomized trials: A case study of morning versus nighttime dosing of blood pressure drugs

Clinical Trials

Volumn 12, Issue 6, 2015, Pages 557-563

  Kim, Scott Y H ^a   Miller, Franklin G ^a,b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

comparative effectiveness research; informed consent; pragmatic trials; research ethics; Standard of care

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ARTICLE; BLOOD PRESSURE MEASUREMENT; CASE STUDY; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE; DRUG SAFETY; ELECTRONIC MEDICAL RECORD; EVENING DOSAGE; EVIDENCE BASED MEDICINE; HEALTH CARE QUALITY; HEART INFARCTION; HUMAN; INFORMED CONSENT; MEDICAL ETHICS; MORNING DOSAGE; NIGHTTIME DOSAGE; PATIENT CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; DRUG ADMINISTRATION; ETHICS; HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIHYPERTENSIVE AGENTS; COMPARATIVE EFFECTIVENESS RESEARCH; DRUG ADMINISTRATION SCHEDULE; HUMANS; HYPERTENSION; INFORMED CONSENT; PRAGMATIC CLINICAL TRIALS AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STANDARD OF CARE;

EID: 84947071047     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774515607213     Document Type: Article

References (33)

1. Olsen L, Aisner D, McGinnis J,. The learning healthcare system (IOM roundtable on evidence-based medicine). Washington, DC: Institute of Medicine of the National Academies, 2007.
2. Califf RM, Platt R,. Embedding cardiovascular research into practice. JAMA 2013; 310: 2037-2038.
3. Lantos J, Feudtner C,. SUPPORT and the ethics of study implementation: lessons for comparative effectiveness research from the trial of oxygen therapy for premature babies. Hastings Cent Rep 2015; 45: 30-40.
4. The Editors. OHRP and standard-of-care research. N Engl J Med 2014; 371: 2125-2126.
5. Magnus D, Caplan AL,. Risk, consent, and SUPPORT. N Engl J Med 2013; 368: 1864-1865.
6. Platt R, Kass NE, McGraw D,. Ethics, regulation, and comparative effectiveness research: time for a change. JAMA 2014; 311: 1497-1498.
7. Kass NE, Faden RR, Goodman SN, et al. The research-treatment distinction: a problematic approach for determining which activities should have ethical oversight. Hastings Cent Rep 2013; 43: S4-S15.
8. Pletcher MJ, Lo B, Grady D,. Informed consent in randomized quality improvement trials: a critical barrier for learning health systems. JAMA Intern Med 2014; 174: 668-670.
9. Faden R, Kass N, Whicher D, et al. Ethics and informed consent for comparative effectiveness research with prospective electronic clinical data. Med Care 2013; 51: S53-S57.
10. Kim SYH, Miller FG,. Varieties of standard-of-care treatment randomized trials: ethical implications. JAMA 2015; 313: 895-896.
11. NIH Collaboratory. Demonstration project ethics and regulatory documentation., https://www.nihcollaboratory.org/demonstration-projects/Pages/default.aspx (. accessed 3 April 2014).
12. Carter BL, Chrischilles EA, Rosenthal G, et al. Efficacy and safety of nighttime dosing of antihypertensives: review of the literature and design of a pragmatic clinical trial. J Clin Hypertens 2014; 16: 115-121.
13. Hermida RC, Ayala DE, Mojón A, et al. Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study. Chronobiol Int 2010; 27: 1629-1651.
14. Verdecchia P,. Prognostic value of ambulatory blood pressure: current evidence and clinical implications. Hypertension 2000; 35: 844-851.
15. Hermida RC, Ayala DE, Mojón A, et al. Decreasing sleep-time blood pressure determined by ambulatory monitoring reduces cardiovascular risk. J Am Coll Cardiol 2011; 58: 1165-1173.
16. Hermida RC, Ayala DE, Mojón A, et al. Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD. J Am Soc Nephrol 2011; 22: 2313-2321.
17. Hermida RC, Ayala DE, Mojón A, et al. Influence of time of day of blood pressure-lowering treatment on cardiovascular risk in hypertensive patients with type 2 diabetes. Diabetes Care 2011; 34: 1270-1276.
18. Ayala DE, Hermida RC, Mojón A, et al. Cardiovascular risk of resistant hypertension: dependence on treatment-time regimen of blood pressure-lowering medications. Chronobiol Int 2013; 30: 340-352.
19. Zhao P, Xu P, Wan C, et al. Evening versus morning dosing regimen drug therapy for hypertension. Cochrane Database Syst Rev 2011; CD004184.
20. Roush GC, Fapohunda J, Kostis JB,. Evening dosing of antihypertensive therapy to reduce cardiovascular events: a third type of evidence based on a systematic review and meta-analysis of randomized trials. J Clin Hypertens 2014; 16: 561-568.
21. American Diabetes Association. Standards of medical care in diabetes-2013. Diabetes Care 2013; 36: S11-S66.
22. American Diabetes Association. 8. Cardiovascular disease and risk management. Diabetes Care 2015; 38: S49-S57.
23. International Society for Chronobiology, American Association of Medical Chronobiology and Chronotherapeutics, Spanish Society of Applied Chronobiology, Chronotherapy, and Vascular Risk, et al. 2013 ambulatory blood pressure monitoring recommendations for the diagnosis of adult hypertension, assessment of cardiovascular and other hypertension-associated risk, and attainment of therapeutic goals. Chronobiol Int 2013; 30: 355-410.
24. Basile JN, Bloch MJ,. Analysis of recent papers in hypertension: nighttime administration of at least one antihypertensive medication is associated with better blood pressure control and cardiovascular outcomes in patients with type 2 diabetes or chronic kidney disease. J Clin Hypertens 2013; 15: 2-4.
25. ClinicalTrials.gov. Prognostic value of the circadian pattern of ambulatory blood pressure for cardiovascular risk assessment (HYGIA), https://clinicaltrials.gov/ct2/show/NCT00741585 (. accessed 18 December 2014).
26. Flack JM,. Is evening dosing of antihypertensive therapy ready for prime time? J Clin Hypertens 2014; 16: 557-558.
27. Orías M, Correa-Rotter R,. Chronotherapy in hypertension: a pill at night makes things right? J Am Soc Nephrol 2011; 22: 2152-2155.
28. Schillaci G, Battista F, Settimi L, et al. Antihypertensive drug treatment and circadian blood pressure rhythm: a review of the role of chronotherapy in hypertension. Curr Pharm Des 2015; 21: 756-772.
29. Gradman AH, Sleep-time blood pressure: a validated therapeutic target. J Am Coll Cardiol 2011; 58: 1174-1175.
30. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002; 288: 2981-2997.
31. Fernandez JR, Hermida RC, Ayala DE, et al. Ambulatory blood pressure monitoring markedly impacts therapeutic decision-making and blood pressure control: the HYGIA Project. J Am Soc Hypertens 2014; 8: e45-e46.
32. Food and Drug Administration. Informed consent information sheet: guidance for IRBs, clinical investigators, and sponsors. Draft Guidance, 2014, http://www.fda.gov/RegulatoryInformation/Guidances/ucm404975.htm
33. Kim SYH, Miller FG,. Informed consent for pragmatic trials-the integrated consent model. N Engl J Med 2014; 370: 769-772.